ERBB2 and breast carcinoma: Considering the results presented in this study, depletion of Her-2-specific IL-5- and IL-17-producing CD4+ T-cells and enrichment of TNF-producing CD8+ T-cells for adoptive T-cell therapy would be important in breast cancer.